NewsBenzingaGenmab, AbbVie Announce Data From Phase 3 EPCORE DLBCL-2 Study Of Epcoritamab Demonstrates Reduction In Disease Progression, Death By 51% For Large B-Cell Lymphoma Genmab, AbbVie Announce Data From Phase 3 EPCORE DLBCL-2 Study Of Epcoritamab Demonstrates Reduction In Disease Progression, Death By 51% For Large B-Cell Lymphoma Benzinga 2026.10.05 18:55 (GMT+0) Open on Benzinga Other news Here’s How Much You Would Have Made Owning Parker Hannifin Stock In The Last 5 Years Backpack Launches Cerebras Tokenized Stock CBRS on Solana, Redeemable 1:1 for Shares Elon Musk is a Trillionaire Again Thanks to SpaceX Stock DeFi Development Corp Adds $3 Million in Solana as SOL Buys Slow $1000 Invested In Tenet Healthcare 15 Years Ago Would Be Worth This Much Today This new AI model could help America close a technological gap with China
